Far-Infrared Therapy Improves Arteriovenous Fistula Patency and Decreases Plasma Asymmetric Dimethylarginine in Patients with Advanced Diabetic Kidney Disease: A Prospective Randomized Controlled Trial

Chun Fan Chen, Chiu Yang Lee, Fu An Chen, Chih Yu Yang, Tz Heng Chen, Shuo Ming Ou, Kuo Hua Lee, Ching Po Li, Chia Hao Chan, Pui Ching Lee, Yung Tai Chen, Tsung Lun Lee, Yang Ho, Fan Yu Chen, Hao Wei Ma, Jinn Yang Chen, Ann Charis Tan*, Szu Yuan Li*, Chih Ching Lin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and plays a significant role in the pathogenesis of arteriovenous fistula (AVF) dysfunction. The aim of this study is to evaluate the effect of far-infrared (FIR) therapy on the maturation and patency of newly-created AVFs in patients with advanced diabetic kidney disease (DKD) as well as the concurrent change in plasma ADMA. The study enrolled 144 participants with advanced DKD where 101 patients were randomly allocated to the FIR therapy group (N = 50) and control group (N = 51). Patients receiving FIR therapy had a decreased AVF failure rate within 12 months (16% versus 35.3%; p = 0.027); decreased incremental change of ADMA concentration at the 3rd and 12th month; increased AVF blood flow at the 1st, 3rd, and 12th month; increased 3-month physiologic maturation rate (88% versus 68.6%; p = 0.034); increased 1-year unassisted AVF patency rate (84% versus 64.7%; p = 0.017); and increased clinical AVF maturation rate within 12 months (84% versus 62.7%; p = 0.029) compared to the control group. The study demonstrates that FIR therapy can reduce the incremental changes in plasma ADMA concentration, which may be associated with the improvement of AVF prognosis in patients with advanced DKD.

Original languageEnglish
Article number4168
JournalJournal of Clinical Medicine
Volume11
Issue number14
DOIs
StatePublished - Jul 2022

Keywords

  • Asymmetric dimethylarginine
  • access blood flow
  • arteriovenous fistula
  • chronic kidney disease
  • diabetic kidney disease
  • far-infrared therapy

Fingerprint

Dive into the research topics of 'Far-Infrared Therapy Improves Arteriovenous Fistula Patency and Decreases Plasma Asymmetric Dimethylarginine in Patients with Advanced Diabetic Kidney Disease: A Prospective Randomized Controlled Trial'. Together they form a unique fingerprint.

Cite this